Další formáty:
BibTeX
LaTeX
RIS
@article{1706278,
author = {Teerlink, JR and Diaz, R and Felker, GM and McMurray, JJV and Metra, M and Solomon, SD and Adams, KF and Anand, I and AriasandMendoza, A and BieringandSorensen, T and Bohm, M and Bonderman, D and Cleland, JGF and Corbalan, R and CrespoandLeiro, MG and Dahlstrom, U and Correa, LEE and Fang, JMC and Filippatos, G and Fonseca, C and Goncalvesova, E and Goudev, AR and Howlett, JG and Lanfear, DE and Lund, M and Macdonald, P and Mareev, V and Momomura, SI and E, O Meara and Parkhomenko, A and Ponikowski, P and Ramires, FJA and Serpytis, P and Sliwa, K and Špinar, Jindřich and Suter, TM and Tomcsanyi, J and Vandekerckhove, H and Vinereanu, D and Voors, AA and Yilmaz, MB and Zannad, F and Sharpsten, L and Legg, JC and Abbasi, SA and Varin, C and Malik, FI and Kurtz, CE},
article_location = {Hoboken},
article_number = {11},
doi = {http://dx.doi.org/10.1002/ejhf.2015},
keywords = {Heart failure; Omecamtiv mecarbil; Cardiac myosin activator; Inotrope; Myotrope; Cardiovascular outcomes trial},
language = {eng},
issn = {1388-9842},
journal = {European Journal of heart Failure},
note = {Bez afiliace k MU.},
title = {Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials},
url = {https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2015},
volume = {22},
year = {2020}
}
TY - JOUR
ID - 1706278
AU - Teerlink, JR - Diaz, R - Felker, GM - McMurray, JJV - Metra, M - Solomon, SD - Adams, KF - Anand, I - Arias-Mendoza, A - Biering-Sorensen, T - Bohm, M - Bonderman, D - Cleland, JGF - Corbalan, R - Crespo-Leiro, MG - Dahlstrom, U - Correa, LEE - Fang, JMC - Filippatos, G - Fonseca, C - Goncalvesova, E - Goudev, AR - Howlett, JG - Lanfear, DE - Lund, M - Macdonald, P - Mareev, V - Momomura, SI - E, O Meara - Parkhomenko, A - Ponikowski, P - Ramires, FJA - Serpytis, P - Sliwa, K - Špinar, Jindřich - Suter, TM - Tomcsanyi, J - Vandekerckhove, H - Vinereanu, D - Voors, AA - Yilmaz, MB - Zannad, F - Sharpsten, L - Legg, JC - Abbasi, SA - Varin, C - Malik, FI - Kurtz, CE
PY - 2020
TI - Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
JF - European Journal of heart Failure
VL - 22
IS - 11
SP - 2160-2171
EP - 2160-2171
PB - Wiley
SN - 13889842
N1 - Bez afiliace k MU.
KW - Heart failure
KW - Omecamtiv mecarbil
KW - Cardiac myosin activator
KW - Inotrope
KW - Myotrope
KW - Cardiovascular outcomes trial
UR - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ejhf.2015
N2 - Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials. Methods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fraction <= 35%, elevated natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency department visit for heart failure within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic-guided dosing: 25, 37.5, or 50 mg bid). A total of 8256 patients [male (79%), non-white (22%), mean age 65 years] were enrolled with a mean ejection fraction 27%, ischaemic aetiology in 54%, NYHA class II 53% and III/IV 47%, and median N-terminal pro-B-type natriuretic peptide 1971 pg/mL. Heart failure therapies at baseline were among the most effectively employed in contemporary heart failure trials. GALACTIC-HF randomized patients representative of recent heart failure registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure <100 mmHg (n = 1127), estimated glomerular filtration rate <30 mL/min/1.73 m(2) (n = 528), and treated with sacubitril/valsartan at baseline (n = 1594). Conclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
ER -
TEERLINK, JR, R DIAZ, GM FELKER, JJV MCMURRAY, M METRA, SD SOLOMON, KF ADAMS, I ANAND, A ARIAS-MENDOZA, T BIERING-SORENSEN, M BOHM, D BONDERMAN, JGF CLELAND, R CORBALAN, MG CRESPO-LEIRO, U DAHLSTROM, LEE CORREA, JMC FANG, G FILIPPATOS, C FONSECA, E GONCALVESOVA, AR GOUDEV, JG HOWLETT, DE LANFEAR, M LUND, P MACDONALD, V MAREEV, SI MOMOMURA, O Meara E, A PARKHOMENKO, P PONIKOWSKI, FJA RAMIRES, P SERPYTIS, K SLIWA, Jindřich ŠPINAR, TM SUTER, J TOMCSANYI, H VANDEKERCKHOVE, D VINEREANU, AA VOORS, MB YILMAZ, F ZANNAD, L SHARPSTEN, JC LEGG, SA ABBASI, C VARIN, FI MALIK a CE KURTZ. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. \textit{European Journal of heart Failure}. Hoboken: Wiley, 2020, roč.~22, č.~11, s.~2160-2171. ISSN~1388-9842. Dostupné z: https://dx.doi.org/10.1002/ejhf.2015.
|
